Brookline Capital Markets Comments on HURA FY2030 Earnings

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Equities research analysts at Brookline Capital Markets cut their FY2030 earnings per share (EPS) estimates for shares of TuHURA Biosciences in a report released on Wednesday, May 27th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings of $0.43 per share for the year, down from their previous forecast of $0.52. The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.51) per share.

Several other equities research analysts have also commented on the company. Citizens Jmp assumed coverage on TuHURA Biosciences in a research note on Monday, April 27th. They set a “market outperform” rating and a $9.00 price target on the stock. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a research note on Wednesday, April 15th. They set a “buy” rating for the company. Citigroup assumed coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an “outperform” rating for the company. Wall Street Zen raised shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, TuHURA Biosciences currently has an average rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Price Performance

Shares of NASDAQ:HURA opened at $2.35 on Friday. The business’s 50 day simple moving average is $2.25 and its 200-day simple moving average is $1.60. The firm has a market capitalization of $149.65 million, a price-to-earnings ratio of -3.85 and a beta of -0.01. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $3.90.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its holdings in TuHURA Biosciences by 24.0% in the 1st quarter. Bank of America Corp DE now owns 78,142 shares of the company’s stock valued at $140,000 after acquiring an additional 15,135 shares during the last quarter. Greenline Wealth Management LLC acquired a new position in TuHURA Biosciences in the 1st quarter valued at $66,000. Merck & Co. Inc. raised its holdings in TuHURA Biosciences by 39.4% in the 1st quarter. Merck & Co. Inc. now owns 19,445 shares of the company’s stock valued at $35,000 after acquiring an additional 5,495 shares during the last quarter. Cetera Investment Advisers acquired a new position in TuHURA Biosciences in the 1st quarter valued at $251,000. Finally, WealthShield Partners LLC acquired a new position in TuHURA Biosciences in the 1st quarter valued at $164,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics using high?dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first?in?class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.